ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 440

Assessing Inappropriate Pain Management in Adults with Hip or Knee Osteoarthritis Treated with Different Opioid Intensity Regimens: Results from a Retrospective Database Analysis

Nathaniel P. Katz1,2, Kavita Gandhi3, Wenhui Wei4, Ahong Huang5 and Li Wang6, 1President, Analgesic Solutions, Natick, MA, 2Tufts University School of Medicine, Boston, MA, 3Director, Global Health Economics and Outcomes Research, Teva Pharmaceutical Industries, Frazer, PA, 4Senior Director, Health Economics and Outcomes Research (HEOR), Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 5Project Manager, STATinMED Research, Dallas, TX, 6Senior Director, Analytic Research, STATinMED Research, Dallas, TX

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: appropriateness, opioids, osteoarthritis and pain management

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, October 21, 2018

Title: Osteoarthritis – Clinical Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Opioids are often prescribed for osteoarthritis (OA) pain management despite the need for balancing their risks and benefits. Since there are no standard criteria for defining inappropriate pain management (IPM), this study examined prevalence of potential criteria that may be indicative of IPM in OA patients (pts) treated with opioids.

Methods: Data were from a US employer-sponsored insurance claims database (2011-2016). Pts were community-dwelling adults (≥18 yr) diagnosed with hip/knee OA who filled an opioid prescription (index event) within 30 days of OA diagnosis; had continuous enrollment 6 months pre- and 12 months post-index; and no pre-index joint surgery. Opioid regimen intensity in the 3-month post-index period was defined by frequency (intermittent: ≤4 d/wk; daily: >4 d/wk), average daily dose in morphine milligram equivalents (MME: <50 MME/d=low, ≥50 MME/d=high), and short- or long-acting opioids (SAO, LAO), providing 6 increasing intensity regimens: intermittent-low-dose SAO, intermittent-high-dose SAO, daily-low-dose SAO, daily-high-dose SAO, LAO, and LAO+SAO. Potential IPM, defined based on existing literature and clinical input (Table 1), comprised 3 clinical categories (Opioid Use, Miscellaneous Drug Use, Medical Service Use). Descriptive analysis characterized prevalence of potential IPM over the 12-month post-index period.
Results: The study included 271,512 pts (61.5% knee; 11.1% hip; 27.4% both); mean age 59.8 yr; 62.7% women. IPM was observed in 52.6% of pts during the post-index period; 30.7% in Miscellaneous Drug Use, 27.7% in Opioid Use, and 14.4% in Medical Service Use. LAO+SAO had the highest IPM (85.4%); intermittent SAO regimens had the lowest (42.7%-44.7%; Table 2). IPM in the intermittent dose regimens was driven by Miscellaneous Drug Use; IPM in the higher intensity regimens was driven by Opioid Use. The top 2 IPM criteria in each clinical category were generally similar across opioid intensity regimens (Table 2).

Conclusion: This study suggests potential criteria indicative of IPM were observed in the majority of OA pts treated with opioids. IPM generally increased with higher opioid intensity regimens; drivers of IPM differed between low and high intensity regimens. The study was limited by the data source and retrospective design such that it could not be determined if IPM resulted from the index opioid treatment regimen itself, patient/physician behavior, or other factors. Nevertheless, study findings reinforce physician need for evaluating pain management with opioids in OA pts individually to ensure optimal health outcomes.


Disclosure: N. P. Katz, Teva, Regeneron, 5; K. Gandhi, Teva, 1, 3; W. Wei, Regeneron, 1, 3; A. Huang, STATinMED Research, 3, 5; L. Wang, STATinMED Research, 3, 5.

To cite this abstract in AMA style:

Katz NP, Gandhi K, Wei W, Huang A, Wang L. Assessing Inappropriate Pain Management in Adults with Hip or Knee Osteoarthritis Treated with Different Opioid Intensity Regimens: Results from a Retrospective Database Analysis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/assessing-inappropriate-pain-management-in-adults-with-hip-or-knee-osteoarthritis-treated-with-different-opioid-intensity-regimens-results-from-a-retrospective-database-analysis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessing-inappropriate-pain-management-in-adults-with-hip-or-knee-osteoarthritis-treated-with-different-opioid-intensity-regimens-results-from-a-retrospective-database-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology